Galapagos NV ended 2022 with a new chief executive and a restructured pipeline that will expand the company’s research and development capabilities into biologics and cell therapies in addition to its traditional small molecule franchise. At a therapeutic level, the company dropped activities in fibrosis and kidney disease and will concentrate on immunology and oncology.
